Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions
Identifieur interne : 000558 ( Ncbi/Merge ); précédent : 000557; suivant : 000559Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions
Auteurs : Moupali Das-DouglasSource :
- AIDS and behavior [ 1090-7165 ] ; 2008.
Abstract
Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.
Url:
DOI: 10.1007/s10461-008-9401-5
PubMed: 18483850
PubMed Central: 3591735
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001F36
- to stream Pmc, to step Curation: 001F35
- to stream Pmc, to step Checkpoint: 002981
Links to Exploration step
PMC:3591735Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions</title>
<author><name sortKey="Das Douglas, Moupali" sort="Das Douglas, Moupali" uniqKey="Das Douglas M" first="Moupali" last="Das-Douglas">Moupali Das-Douglas</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">18483850</idno>
<idno type="pmc">3591735</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591735</idno>
<idno type="RBID">PMC:3591735</idno>
<idno type="doi">10.1007/s10461-008-9401-5</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">001F36</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001F36</idno>
<idno type="wicri:Area/Pmc/Curation">001F35</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001F35</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002981</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002981</idno>
<idno type="wicri:Area/Ncbi/Merge">000558</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions</title>
<author><name sortKey="Das Douglas, Moupali" sort="Das Douglas, Moupali" uniqKey="Das Douglas M" first="Moupali" last="Das-Douglas">Moupali Das-Douglas</name>
</author>
</analytic>
<series><title level="j">AIDS and behavior</title>
<idno type="ISSN">1090-7165</idno>
<idno type="eISSN">1573-3254</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9712133</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21042</journal-id>
<journal-id journal-id-type="nlm-ta">AIDS Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">AIDS Behav</journal-id>
<journal-title-group><journal-title>AIDS and behavior</journal-title>
</journal-title-group>
<issn pub-type="ppub">1090-7165</issn>
<issn pub-type="epub">1573-3254</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">18483850</article-id>
<article-id pub-id-type="pmc">3591735</article-id>
<article-id pub-id-type="doi">10.1007/s10461-008-9401-5</article-id>
<article-id pub-id-type="manuscript">NIHMS447651</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Das-Douglas</surname>
<given-names>Moupali</given-names>
</name>
</contrib>
<aff id="A1">Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
<aff id="A2">Center for AIDS Prevention Studies, University of California, San Francisco, CA 94105, USA</aff>
<aff id="A3">HIV Prevention Section, AIDS Office, San Francisco Department of Public Health, 25 Van Ness, Suite 500, San Francisco, CA 94102, USA</aff>
<aff id="A4">Epidemiology and Prevention Interventions Center, San Francisco General Hospital, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
<aff id="A5">Positive Health Program, San Francisco General Hospital, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="author"><name><surname>Riley</surname>
<given-names>Elise D.</given-names>
</name>
</contrib>
<aff id="A6">Epidemiology and Prevention Interventions Center, San Francisco General Hospital, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="author"><name><surname>Ragland</surname>
<given-names>Kathleen</given-names>
</name>
</contrib>
<aff id="A7">Epidemiology and Prevention Interventions Center, San Francisco General Hospital, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="author"><name><surname>Guzman</surname>
<given-names>David</given-names>
</name>
</contrib>
<aff id="A8">Epidemiology and Prevention Interventions Center, San Francisco General Hospital, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="author"><name><surname>Clark</surname>
<given-names>Richard</given-names>
</name>
</contrib>
<aff id="A9">Epidemiology and Prevention Interventions Center, San Francisco General Hospital, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="author"><name><surname>Kushel</surname>
<given-names>Margot B.</given-names>
</name>
</contrib>
<aff id="A10">Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<contrib-group><contrib contrib-type="author"><name><surname>Bangsberg</surname>
<given-names>David R.</given-names>
</name>
</contrib>
<aff id="A11">Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
<aff id="A12">Epidemiology and Prevention Interventions Center, San Francisco General Hospital, Division of Infectious Diseases, University of California, San Francisco, CA 94143, USA</aff>
<aff id="A13">Positive Health Program, San Francisco General Hospital, University of California, San Francisco, CA 94143, USA</aff>
</contrib-group>
<author-notes><corresp id="CR1"><email>moupali.das-douglas@ucsf.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>26</day>
<month>2</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="epub"><day>16</day>
<month>5</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="ppub"><month>2</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>08</day>
<month>3</month>
<year>2013</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>9</lpage>
<permissions><copyright-statement>© Springer Science+Business Media, LLC 2008</copyright-statement>
<copyright-year>2008</copyright-year>
</permissions>
<abstract><p id="P1">Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.</p>
</abstract>
<kwd-group><kwd>HIV/AIDS</kwd>
<kwd>Medicare</kwd>
<kwd>Adherence</kwd>
<kwd>Treatment interruption</kwd>
<kwd>Cost-sharing</kwd>
<kwd>Cost-related medication nonadherence</kwd>
</kwd-group>
<funding-group><award-group><funding-source country="United States">National Institute of Mental Health : NIMH</funding-source>
<award-id>R01 MH054907 || MH</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Das Douglas, Moupali" sort="Das Douglas, Moupali" uniqKey="Das Douglas M" first="Moupali" last="Das-Douglas">Moupali Das-Douglas</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000558 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000558 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:3591735 |texte= Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:18483850" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SidaSubSaharaV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |